PAR-25-336-Full-Announcement.html

This Notice of Funding Opportunity (NOFO), designated as PAR-25-336, is issued by the National Cancer Institute (NCI) under the Department of Health and Human Services to support advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. The funding opportunity focuses on maturing experimental nanomedicines that utilize nanoparticles and nano-devices to improve cancer treatment effectiveness through structural design and therapeutic/diagnostic cargo delivery.

The grant opportunity falls under the Cancer Treatment Research program (CFDA 93.395) and is open to a wide range of applicants including higher education institutions, government entities, nonprofits, for-profit organizations, tribal organizations, and small businesses. The primary goal is to develop nanotechnology-based interventions to a stage where they can progress to the NCI Experimental Therapeutics (NExT) program and other NCI translational programs. The funding instrument is a grant through an R01 mechanism that does not allow clinical trials.